annb0t
Top 20
Immutep Limited (NASDAQ: IMMP) provides a clinical development update for its lead product candidate, eftilagimod alpha (efti). Based on compelling data, the company is prioritizing 1L NSCLC in terms of late-stage clinical strategy. Together with Merck & Co Inc's (NYSE: MRK) Keytruda, efti has been delivering solid results. Immutep's next steps in NSCLC will be shaped by the maturing TACTI-002 data, with additional data expected in Q4 2022 and feedback from regulatory authorities. The company...
>>> Read more: Immutep Issues Development Update For Its Lead Cancer Candidate
>>> Read more: Immutep Issues Development Update For Its Lead Cancer Candidate
